As otolaryngologists play increasingly important roles in the evaluation and treatment of sleep disordered breathing, it is important that all practitioners systematically study the fi eld of sleep. The curriculum outlined in this article has been developed fo r resident training at the University of California, San Diego, School of Medicine. It is divided into goals and objectives, curriculum, differential diagnosis of sleep disordered breathing, international class ification of sleep disordered breathing, a glossary of sleep terms, and a list of resources. From the Dep artment of Otolaryngology-H ead and Neck Surgery (Dr. Davidson ) and the Divi sion of Pulm onary Physiology (Dr. Lored o). Uni versit y of Ca liforni a, San Diego. Sch ool o f Medicine and the VA San Diego Hea lthcare System . Repri nt req uest s: Terenc e M. Davidson . MD , VA San Diego Hea lthcar e System ( 112C).
Goals and objectives
Oto laryngologists play an important role in the evaluation and trea tme nt of patie nts with slee p disordered breat hing, with special emphasis and expertise in obstructive sleep apnea , snoring, and upper airway resistance syndrome. The follow ing curriculum is designed to prov ide the oto lary ngo logis t with the requisi te know ledge in the basic and clinica l sciences of sleep so that they can independe ntly eva luate and treat patients with sleep disordered breathing and participate in multidisciplinary team practices.
Curriculum
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